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Abstract
Background: Cognitive dysfunction is a frequent complication to open-heart surgery. Cerebral inflammation
caused by blood-brain barrier (BBB) dysfunction due to a systemic inflammatory response is considered a
possible etiology. The effects of the glucocorticoid, methylprednisolone, on cerebrospinal fluid (CSF) markers
of BBB function, neuroinflammation, and brain injury in patients undergoing cardiac surgery with cardiopulmonary
bypass were studied.
Methods: In this prospective, randomized, blinded study, 30 patients scheduled for elective surgical aortic valve
replacement were randomized to methylprednisolone 15 mg/kg (n = 15) or placebo (n = 15) as a bolus dose
administered after induction of anesthesia. CSF and blood samples were obtained the day before and 24 h
after surgery for assessment of systemic and brain inflammation (interleukin-6, interleukin-8, tumor necrosis
factor-alpha), axonal injury (total-tau, neurofilament light chain protein), neuronal injury (neuron-specific
enolase), astroglial injury (S-100B, glial fibrillary acidic protein), and the BBB integrity (CSF/serum albumin ratio).
Results: In the control group, there was a 54-fold and 17-fold increase in serum interleukin-6 and interleukin-8,
respectively. This systemic activation of the inflammatory cytokines was clearly attenuated by methylprednisolone (p < 0.
001). The increase of the CSF levels of the astroglial markers was not affected. A postoperative BBB dysfunction was seen
in both groups as the CSF/serum albumin ratio increased from 6.4 ± 8.0 to 8.0 in the placebo group (p < 0.01) and from 5.
6 ± 2.3 to 7.2 in the methylprednisolone group (p < 0.01) with no difference between groups (p = 0.98). In the
CSF, methylprednisolone attenuated the interleukin-6 release (p < 0.001), which could be explained by the fall
in systemic interleukin-6, and the serum to CSF gradient of IL-6 seen both at baseline and after surgery. In the
CSF, methylprednisolone enhanced the interleukin-8 release (p < 0.001) but did not affect postoperative changes in CSF
levels of tumor necrosis factor alpha. Serum levels of S-100B and neuron-specific enolase increased in both groups with
no difference between groups. CSF levels of total tau, neurofilament light chain protein, and neuron-specific enolase
were not affected in any of the groups.
Conclusions: Preventive treatment with high-dose methylprednisolone attenuated the systemic inflammatory response
to open-heart surgery with cardiopulmonary bypass, but did not prevent or attenuate the increase in BBB permeability or
the neuroinflammatory response.
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Background
Neurological complications to open-heart surgery re-
main a common cause of postoperative morbidity [1, 2].
They span from the, often reversible, condition of post-
operative cognitive dysfunction (POCD) and delirium to
manifest stroke. The, possibly multifactorial, etiology re-
mains unclear but arteriosclerosis, cerebral microemboli-
zation originating from cardiopulmonary bypass (CPB),
cerebral inflammation, blood-brain barrier (BBB) disrup-
tion, and cerebral hypoperfusion/hypooxygenation have
been suggested as possible causes [3].
Experimental studies have suggested that surgical
trauma induces a systemic inflammatory response caus-
ing a disruption of the blood-brain, neuroinflammation,
and cognitive dysfunction [4, 5]. Cardiac surgery is asso-
ciated with a profound systemic inflammatory response
due to the surgical trauma and the interaction between
blood and the artificial surfaces of the CPB circuit [6].
Previous studies have demonstrated the presence of
brain edema early after cardiac surgery with CPB [7, 8],
which could to some degree be explained by a BBB dys-
function [3, 9].
In a previous study, we studied the release of cerebro-
spinal fluid markers of inflammation, neuronal and glial
cell injuries, and BBB function after cardiac surgery with
CPB [10]. A pronounced cerebral inflammatory response
was found together with glial cell injury and BBB dys-
function, without biochemical signs of neuronal injury.
High doses of corticosteroids can be used to suppress the
postoperative systemic inflammatory response syndrome in
cardiac surgery [11]. Methylprednisolone is a synthetic
glucocorticoid, which has been shown to suppress the re-
lease of systemic pro-inflammatory cytokines in patients
exposed to cardiac surgery with CPB [11]. If the neuroin-
flammatory response to cardiac surgery with CPB is trig-
gered by a systemic inflammation, an inhibition of this
systemic inflammation by high-dose corticosteroids could
potentially attenuate this neuroinflammatory response.
In this randomized trial, we aimed to assess the effects of
an intraoperative high dose of methylprednisolone on CSF
markers of neuroinflammation, brain injury, and blood-
brain barrier function in patients undergoing cardiac sur-
gery with CPB. Our hypothesis was that the previously de-
scribed neuroinflammatory response to cardiac surgery is
attenuated by a high dose of methylprednisolone.
Methods
This prospective, randomized, blinded, double-armed study
was approved by The Gothenburg Regional Ethics Com-
mittee (www.epn.se/goeteborg/) and the Swedish Medical
Product Agency, and all patients signed an informed, writ-
ten consent preoperatively. The study was registered at
www.clinicaltrials.gov; identifier: NCT01755338, first
posted 24 December 2012 by Mattias Danielson. This study
adheres to the applicable CONSORT guidelines (see
Additional file 1).
Patients
Between January 2013 and January 2017, we enrolled 30
patients in a prospective, randomized, blinded, double-
armed study. Inclusion criteria were (a) elective open
aortic valve replacement surgery (SAVR) with a bio-
logical valve prosthesis due to aortic stenosis with or
without concurrent coronary artery bypass grafting
(CABG), (b) normal preoperative coagulation tests (i.e.,
partial thromboplastin time < 45 s and prothrombin time
[international normalized ratio] < 1.5 and a platelet
count > 80,000), (c) absence of recent (< 1 week) treatment
with thrombolytic or potent anti-platelet drugs, and (d) pre-
operative left ventricular ejection fraction ≥ 50%. Exclusion
criteria were (a) stroke with sequelae and (b) abnormal co-
agulation tests (see above) or thromboelastograms in the
morning on the day after surgery.
Experimental protocol
A randomized block design was used based on gender
and type of surgery (SAVR or SAVR plus CABG). Pa-
tients were randomized to treatment with either methyl-
prednisolone (Solu-Medrol , Pfizer) 15 mg/kg or
placebo (0.9% sodium-chloride) administered after in-
duction of anesthesia. A nurse, not involved in the study
or care of the patients, randomized the patients to the
study drugs in a 1:1 ratio, using concealed, sequentially
numbered opaque envelopes. This nurse prepared the
drugs and performed the blinding.
Anesthesia and cardiopulmonary bypass
Premedication consisted of oxazepam 10 mg, oxycodone
10 mg, and half the dose of any ongoing beta-adrenergic
blocker treatment orally. A catheter was placed in the
radial artery before the induction of anesthesia for blood
sampling and continuous monitoring of mean arterial
blood pressure (MAP). Anesthesia was induced with fen-
tanyl (5–10 μg/kg), propofol (1–1.5 mg/kg), and rocuro-
nium (0.6 mg/kg). Before and after cardiopulmonary
bypass (CPB), anesthesia was maintained with sevoflur-
ane 0.5–2.5% in a 50% O2/air mixture, whereas propofol
(2.5–4 mg/kg/h) was used during CPB. MAP was main-
tained within the range 70–80 in the pre- and post-CPB
period, and a MAP within the range of 60–80 mmHg
during CPB using phenylephrine and/or norepinephrine
when necessary.
The CPB perfusion system consisted of a hollow fiber
membrane oxygenator and a Stöckert S-5 (Sorin Group).
The pump was primed with acetated Ringer’s solution and
mannitol, with the target CPB flow rate of 2.4 l/min/m2
and the target hematocrit of 25–35%. PaCO2 was main-
tained at 40–48 mmHg and was uncorrected for body
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temperature. PaO2 was maintained at 180–260 mmHg, and
SvO2 was maintained at > 65%. During CPB, the body
temperature was maintained at 36 °C in all patients. During
the peri- and postoperative period, the target serum glucose
level was 4.2–6.3 mmol/l using a standardized insulin infu-
sion protocol when appropriate.
Cerebrospinal fluid (CSF) and serological markers of
inflammation, brain injury, and blood-brain barrier
function
A lumbar puncture for quantitative analysis of CSF
biomarkers was performed the day before surgery and ap-
proximately 24 h after surgery. We used a 27-G Whitacre
spinal needle (Becton Dickinson S.A. S. Agustin del Guada-
lix, Madrid, Spain) for median approach at L3–4 level in
the sitting position. A CSF sample volume of 2.5 ml and a
4 ml blood sample were collected at both time points.
Detailed information on the measurements of CSF and
serological markers of inflammation, brain injury, and
blood-brain barrier function are shown in Additional file 2.
Statistical analysis
The primary end-point was the intergroup difference in
postoperative IL-8. A power analysis was performed,
based on our previous study [10]. To detect a 50% differ-
ence in CSF IL-8 between groups, 13 patients were
needed in each group at a power of 0.80 and α of 0.05
and a standard deviation of 60 ng/L. Continuous vari-
ables were checked for normal distribution using the
Shapiro-Wilk test. Within-group differences where
compared using paired Student’s t test or Wilcoxon
signed-rank test when appropriate. The comparison of the
effects of surgery on changes of the various variables be-
tween the placebo and intervention groups were tested
using an unpaired Student’s t test or Mann-Whitney U
test. All data are presented as mean ± standard deviation
(SD) or median and interquartile range (IQR) when ap-
propriate. A probability level (p value) of less than 0.05
was considered to indicate statistical significance. Statis-
tical analysis was performed using SPSS for Macintosh,
version 24.
Results
The clinical trial profile is summarized in Fig. 1. The two
groups were well matched with respect to age, gender,
body weight, comorbidity, cardiac status, EuroSCORE II,
and type of surgery (Table 1). The pre- and postoperative
lumbar punctures were uneventful in all patients and in
none of the patients was there a bloody tap or post-spinal
headache. Intra-procedural data are presented in Table 2.
There were no differences between groups with respect to
durations of procedure, extracorporeal circulation, or aor-
tic cross-clamp. Perioperative blood glucose levels did not
differ between groups. There was a statistically significant
increase in insulin requirement in the methylprednisolone
group. Postoperatively, serum creatinine, the need for
hemodynamic support, reoperation for bleeding, ICU re-
admission, incidence of atrial fibrillation/flutter, neuro-
logical complications, the incidence of infections, or
length of ICU/hospital stay did not differ between groups.
Fig. 1 Study flow chart
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Systemic response to cardiac surgery (Table 3)
In the control group, there was a 54-fold and 17-fold in-
crease in serum IL-6 and IL-8, respectively. This sys-
temic cytokine activation by cardiac surgery was clearly
attenuated by methylprednisolone treatment (p < 0.001).
Serum levels of TNF-α were not changed in the control
group but decreased in the methylprednisolone group
after cardiac surgery. Serum S-100B increased in both
groups, but showed no difference between groups.
Serum albumin decreased in both groups with no differ-
ence between groups.
Central nervous system response to cardiac surgery
(Table 4)
Astroglial injury
There was a trend for an increase in CSF levels of
S-100B in the methylprednisolone group with no differ-
ences between groups. CSF levels of GFAP were not sig-
nificantly affected in any of the groups.
Neuronal injury
CSF levels of NSE or NFL were not affected by cardiac
surgery in either of the groups. CSF levels of total tau
(T-tau) decreased (− 19%) after cardiac surgery in the
control but not in the methylprednisolone group.
Blood-brain barrier (BBB) integrity
The CSF to serum albumin ratio increased postopera-
tively in both the control and methylprednisolone group
by 20–25%, with no difference between groups.
Neuroinflammation
CSF levels of TNF-α increased slightly in both the con-
trol and the methylprednisolone group after cardiac sur-
gery with no difference between groups. There was a
marked (8-fold) increase in CSF IL-6 in the control
group, which was attenuated by methylprednisolone
(2.4-fold increase, p = 0.001). Cardiac surgery induced a
3.4-fold increase in CSF-IL-8 in the control group. In
the methylprednisolone group, cardiac surgery caused a
7.5-fold increase in CSF-IL-8 (p < 0.001).
Discussion
The main findings were that on-pump cardiac surgery
induced a systemic inflammatory response, which was
accompanied by a dysfunction of the BBB and a neu-
roinflammatory response. Furthermore, although intra-
Table 1 Demographic, clinical, and surgical characteristics of the groups
Characteristics Placebo (n = 15) Methylprednisolone (n = 15)
Demographics
Age (years) 68.9 ± 11 70.7 ± 7.0
Male sex (n) 13 10
Body weight (kg) 81.1 ± 9.0 82.5 ± 15.7
Height (cm) 173 ± 7.0 176 ± 7.9
Comorbidity
Hypertension (n) 9 9
Previous heart surgery (n) 0 0
Atrial fibrillation/flutter (n) 1 0
Serum creatinine (μmol/l) 89.7 ± 15 88.3 ± 20
Cardiac status
LVEF, % 60 ± 4.2 61 ± 5.8
NYHA
I (n) 7 4
II (n) 4 9
III (n) 4 2
IV (n) 0 0
EuroSCORE II, % 1.8 ± 1.4 1.9 ± 1.5
Type of surgery
SAVR (n) 10 11
CABG + SAVR (n) 5 4
Values are mean ± SD. CAGB coronary artery bypass grafting, LVEF left ventricular ejection fraction, NYHA New York Heart association, SAVR surgical aortic valve repair
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operative preemptive treatment with a high dose of
methylprednisolone, clearly attenuated the systemic in-
flammatory response, it did not prevent/attenuate the
BBB dysfunction or the neuroinflammatory response in-
duced by this procedure.
Cardiac surgery induced a moderate, 25% increase of the
CSF to serum albumin ratio, which confirms findings from
our previous study [10]. A BBB dysfunction after cardiac
surgery was also demonstrated by Merino et al. who found
that almost 50% of the patients had signs of BBB disruption
as demonstrated by magnetic resonance imaging [9]. In-
creased permeability of the BBB for large molecules might
explain the previously observed brain edema in patients
undergoing uncomplicated on-pump cardiac surgery [8]. It
has been suggested that intra-operative microembolization
and the interaction between gaseous or solid cerebral
Table 2 Intra- and postoperative characteristics of the groups
Characteristics Placebo (n = 15) Methylprednisolone (n = 15) p value
Intraoperative data
Duration of procedure (min) 189 ± 43 204 ± 58 0.43
Duration of CPB (min) 99.4 ± 25 115 ± 31 0.14
Duration of aortic cross-clamping (min) 81.5 ± 25 91.7 ± 29 0.28
Intra-operative dose of phenylephrine (mg) 1.02 ± 1.1 1.36 ± 1.0 0.39
Intra-operative dose of norepinephrine (mg) 0.58 ± 1.3 0.56 ± 0.55 0.95
Plasma glucose levels 0.096
Start of procedure (mmol/l) 6.34 ± 1.5 5.25 ± 0.47
During CPB (mean), (mmol/l) 6.52 ± 0.94 7.25 ± 1.0
After CPB (mmol/l) 7.15 ± 0.97 8.50 ± 1.7
Arrival ICU (mmol/l) 6.20 ± 0.5 7.20 ± 1.6
Day 1 ICU (mmol/l) 6.27 ± 1.2 6.44 ± 1.2
Insulin demand U/hour (intraoperatively + ICU) 1.14 ± 0.74 2.46 ± 1.27 0.009
Postoperative data
Serum creatinine (μmol/l) 83.9 ± 18 94.9 ± 21 0.14
Vasopressor treatment, n 6 9 0.47
Inotropic treatment (n) 0 0 1.0
Reoperation for bleeding (n) 0 0 1.0
ICU readmission (n) 0 1 1.0
Atrial fibrillation/flutter, (n) 5 10 0.14
Neurological complication, (n) 2 1 1.0
Pneumonia, (n) 0 1 1.0
Wound infection, (n) 1 1 1.0
Other infection, (n) 0 2 0.48
Length of stay in ICU (hours) 24.8 ± 14 22.7 ± 12 0.65
Values are mean ± SD. CPB cardiopulmonary bypass, ICU intensive care unit. **p < 0.01
Table 3 Systemic response to cardiac surgery
Placebo (n = 15) Methylprednisolone (n = 15) Between group
analysis, p valuePreoperative Postoperative Preoperative Postoperative
Serum TNF-α (ng/L)# 2.45 (0.88) 2.15 (0.68) 2.36 (1.14) 1.54 (0.83)*** < 0.001
Serum IL-6 (ng/L)# 0.86 (0.82) 49.1 (48)*** 0.99 (0.85) 14.6 (8.8)*** < 0.001
Serum IL-8 (ng/L) 14.2 ± 5.4 40.9 ± 23*** 12.4 ± 4.8 19.2 ± 15 0.004
Serum S-100B (μg/L)# 0.060 (0.027) 0.116 (0.07)* 0.044 (0.03) 0.126 (0.06)** 0.48
Serum albumin (g/L) 43.2 ± 4.8 35.1 ± 4.5*** 43.2 ± 3.3 35.9 ± 2.9*** 0.65
Serum NSE (μg/L)# 14.9 (14) 27.6 (7.6)* 13.8 (8.2) 31.1 (12)* 0.27
Values are mean ± SD or median (IQR)#; not normally distributed data—non-parametric tests used. IL-6 interleukin-6, IL-8 interleukin-8, NSE neuron-specific
enolase, TNF-α tumor necrosis factor alpha. *p < 0.05, **p < 0.01, ***p < 0.001, within-group
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emboli and the cerebral vascular endothelium might cause
an activation of endothelial cells causing a secondary im-
paired permeability of the BBB [3, 12].
Another explanation for the increased permeability of
the BBB could be the systemic inflammatory response
syndrome induced by the surgical trauma. Experimental
studies have shown that a peripheral sterile surgical
trauma activates the innate immune system to release
pro-inflammatory cytokines, increasing BBB permeabil-
ity, which, in turn, will trigger inflammatory processes
particularly of the hippocampal region mediated by
macrophage migration through the BBB. This cerebral
inflammatory response to trauma subsequently induced
postoperative cognitive function in this experimental
model [4, 5]. In the present study, we administered a
high dose of the glucocorticoid, methylprednisolone,
which induced a pronounced attenuation of the systemic
cytokines TNF-α, IL-6, and IL-8, which has previously
been described in several studies [13, 14]. Based on pre-
vious experimental studies, we hypothesized that such
an inhibition of the systemic inflammation could pre-
vent/attenuate the BBB dysfunction and the neuroin-
flammation seen after cardiac surgery. However, BBB
permeability and CSF levels of TNF-α increased to a
similar extent in both groups. Furthermore, there was a
considerably more pronounced increase in the CSF IL-8
in the methylprednisolone group, suggesting a direct
production of immune-related cells within the brain it-
self. On the other hand, the release of IL-6 was attenu-
ated in the methylprednisolone group. However, changes
in the CSF levels of IL-6 must be interpreted with cau-
tion, as there is a serum to CSF gradient of IL-6 both at
baseline and after surgery, in contrast to what is seen for
IL-8. In other words, the methylprednisolone-induced
attenuation of the CSF IL-6 release could be explained
by the pronounced attenuation of serum IL-6 release
and consequently less passive spill-over to the CSF.
Thus, the results of the present study do not support the
hypothesis that the systemic inflammatory response in-
duced by surgical trauma causes a BBB dysfunction
followed by a neuroinflammatory response.
It has been suggested that increased serum levels of
neuronal and glial cell injury biomarkers, such as
S-100B and NSE, are associated with cerebral injury and
POCD in on-pump cardiac surgery [15–17]. These stud-
ies may, however, be flawed as S-100B may originate
from extracerebral sources [18] and serum levels of NSE
may be derived from hemolysis during cardiopulmonary
bypass [19]. The most appropriate approach to assess
neuronal or glial cell injury would be to perform mea-
surements of established biomarkers in the CSF, which
is in direct contact with cerebral interstitial fluid. NSE is
an enolase-isoenzyme found in neuronal and neuroen-
docrine tissues. Its levels in other tissues, except erythro-
cytes, are negligible. T-tau is released from unmyelinated
cortical axons and NFL is released from subcortical
myelinated axons. Data on CSF levels of neuronal and
glial cell injury biomarkers before and after on-pump
cardiac surgery are scarce [20, 21]. In the present study,
we found no evidence of a cardiac surgery-induced neur-
onal injury as neither of the neuronal injury markers
were elevated after surgery in the control or the methyl-
prednisolone group. If anything, CSF levels of T-tau de-
creased after surgery in the control group. These
findings are in line with those of Kaukinen et al. who
showed that on-pump normothermic or hypothermic
cardiac surgery did not cause a release of NSF into the
CSF when measured days and months after the
Table 4 Cerebral response to cardiac surgery
Placebo (n = 15) Methylprednisolone (n = 15) Between group
analysis, p valuePreoperative Postoperative Preoperative Postoperative
CSF S-100B (μg/L)# 0.94 (0.26) 0.88 (0.42) 0.94 (0.36) 1.14 (0.54)* 0.47
CSF GFAP (ng/l) 643 ± 387 683 ± 388 684 ± 412 763 ± 422 0.54
CSF NSE (μg/L)# 4.55 (2.2) 4.82 (2.7) 3.60 (3.9) 6.15 (3.7) 0.36
CSF NFL (ng/L) 990 ± 442 1031 ± 442 1125 ± 583 1120 ± 527 0.43
CSF T-tau (ng/L)# 295 (233) 301 (269)* 324 (111) 288 (156) 0.085












CSF TNF-α (ng/L)# 0.15 (0) 0.15 (0.08)** 0.15 (0) 0.15 (0.06)* 0.905
CSF IL-6 (ng/L) 0.833 ± 0.23 6.69 ± 4.9*** 1.01 ± 0.39 2.44 ± 1.5** 0.001
CSF IL-8 (ng/L)# 40.0 (13) 130 (93)*** 46.0 (15) 321 (275)*** < 0.001
Values are mean ± SD, or median (IQR)#; not normally distributed data—non-parametric tests used. CSF cerebrospinal fluid, GFAP glial fibrillary acidic protein, IL-6
interleukin-6, IL-8 interleukin-8, NSE neuron-specific enolase, NFL neurofilament light chain protein, T-tau total tau, TNF-α tumor necrosis factor alpha. *p < 0.05, **p
< 0.01, ***p < 0.001, within-group
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procedure [20] and results from our previous study
showing that CSF levels of NSE, NFL, and T-tau were
not elevated 24 h after on-pump cardiac surgery [10]. In
the latter study, we found that the majority of cerebral
emboli, as detected by transcranial Doppler, appeared
during weaning from CPB, with a high probability of less
harmful air emboli, with less cerebral flow disturbances
than solid emboli. A limitation of our study is that we
could not perform CSF sampling at later time points
than 24 h post-surgery. Longitudinal studies following
stroke suggest that the optimal time point to detect
neuronal injury using CSF biomarkers is 7–10 days
post-injury [22].
Data on the mechanism(s) behind the increased per-
meability of the BBB are not provided in the present
study. Irrespective of the cause of the dysfunction of the
BBB, it could not be prevented or attenuated by
methylprednisolone.
IL-8 is a pro-inflammatory cytokine which attracts
neutrophils as mediators of inflammation [23]. In the
present study, methylprednisolone induced a more
profound, 7.5-fold increase in CSF IL-8 after surgery
compared to the 3.4-fold increase in the control group
(Fig. 2). Data on the effects of systemic administration of
a glucocorticoid on CSF levels of IL-8 are scarce. In a re-
cent study, on the effects of intrathecal injection of
methylprednisolone on postherpetic neuralgia, CSF IL-8
increased 8–9 times while the cyto/chemokines IL-1,
IL-10, and TNF-α were not affected over time, compared
to controls [24]. Furthermore, in a human microvascular
endothelial cell line, glucocorticoids were shown to en-
hance ATP-induced vascular endothelial cytokine pro-
duction, augmenting the release of IL-8. Thus, it seems
that glucocorticoids may enhance the production of IL-8
in endothelial inflammation [25].
One limitation was that CSF levels of biomarkers were
obtained only once after the surgical procedure. Thus, a
more detailed evolution of the CSF biomarkers over time
could not be assessed. However, it was too risky to perform
more than one postoperative lumbar puncture for quan-
titative analysis of CSF, as anticoagulant and anti-platelet
therapy was commenced on the first postoperative day.
Furthermore, we did not measure anti-inflammatory cyto-
kines, which could have provided information on the effects
of cardiac surgery on the balance between pro- and
anti-inflammatory mediators in the CSF and the potential
effect of preemptive methylprednisolone on this balance.
Conclusions
In conclusion, we showed that preventive treatment with
high-dose methylprednisolone attenuated the systemic
inflammatory response to cardiac surgery with CPB, but
this treatment did not prevent or attenuate the increase
Fig. 2 The individual data on the pre- and postoperative levels of serum and cerebrospinal fluid (CSF) levels of interleukin-8 (IL-8). The increase in
serum levels of IL-8 seen after surgery was clearly attenuated by methylprednisolone (steroid), while methylprednisolone induced a pronounced
accentuation of the CSF IL-8 response to cardiac surgery
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in BBB permeability or the neuroinflammatory response
seen after this procedure.
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